An Updated Review on the Therapeutic, Diagnostic, and Prognostic Value of Long Non-Coding RNAs in Gastric Cancer

Curr Med Chem. 2022;29(19):3471-3482. doi: 10.2174/0929867328666211115121019.

Abstract

As a novel group of non-coding RNAs, long non-coding RNA (lncRNAs) can substantially regulate various biological processes. Downregulated tumor-suppressive lncRNAs and upregulated oncogenic lncRNAs (onco-lncRNAs) have been implicated in gastric cancer (GC) development. These dysregulations have been associated with decreased chemosensitivity, inhibited apoptosis, and increased tumor migration in GC. Besides, growing evidence indicates that lncRNAs can be a valuable diagnostic and prognostic biomarker, and their expression levels are substantially associated with the clinicopathological features of affected patients. The current study aims to review the recent findings of the tumor-suppressive lncRNAs and onco-lncRNAs in GC development and highlight their therapeutic, diagnostic, and prognostic values in treating GC cells. Besides, it intends to highlight the future direction of lncRNAs in treating GC.

Keywords: LncRNAs; biomarkers; diagnosis; gastric cancer; oncogenic; prognosis; tumor-suppressive.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Prognosis
  • RNA, Long Noncoding* / genetics
  • Stomach Neoplasms* / diagnosis
  • Stomach Neoplasms* / drug therapy
  • Stomach Neoplasms* / genetics

Substances

  • Biomarkers, Tumor
  • RNA, Long Noncoding